LMO3 downregulation in PCa: A prospective biomarker associated with immune infiltration

LMO3 downregulation in PCa: A prospective biomarker associated with immune infiltration

Prostate cancer is the third leading cause of new cancer cases and the second most common tumor type in men globally. LMO3 has been stated to play a vital role in some cancers; however, the prognostic value of LMO3 in PCa remains vague. Here, we utilized various web databases to elucidate in detail...

Full description

Bibliographic Details
Main Authors: Wenchao Xu, Taotao Sun, Jiaxin Wang, Hao Li, Bingliang Chen, Yingjian Zhou, Tao Wang, Shaogang Wang, Jihong Liu, Hongyang Jiang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Genetics
Subjects:
LMO3
prostate cancer
biomarker
immune infiltration
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2022.945151/full

Internet

https://www.frontiersin.org/articles/10.3389/fgene.2022.945151/full

Similar Items